Pharmafile Logo

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. Last year the FDA approved 48 drugs in rare diseases, including both novel and repurposed drugs.

Rare diseases are attractive to pharma for a number of reasons. Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced regulatory fees, tax incentives and line extensions. Secondly, although patient populations for each disease in every market are small, if the drug gains approval across a number of indications, the manufacturer can increase its potential revenue. Thirdly, if successful, manufacturers have the opportunity to be a market leader in a niche area.

Find out more:
www.researchpartnership.com/news/2016/01/pharma-market-research-report-predictions-for-2016/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.

Case study: How segmentation of treaters guided a novel product launch in the allergy space

Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment...

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.

Research Partnership wins prestigious 2023 BOBI Award

We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.

Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market

Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.